Clinical Trials Browser

Completed × bemcentinib × Clear all

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT02424617 2025-02-26

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT06469138 2025-01-29

8479217

Phase 1 Completed

6 enrolled 17 charts

CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Phase 1/2 Completed

122 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02922777 2024-02-21

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03824080 2021-12-21

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute